| April 17, 2007, San Diego --
Cardium Therapeutics (OTCBB:CDTP) today announced that its Phase
3 product
candidate
being developed for the potential treatment of myocardial ischemia
and associated angina will employ an automated infusion system
manufactured for Cardium by Caesarea Medical Electronics Ltd. The
automated infusion system will be used in Cardium's Phase 3 AWARE
study to standardize the cardiac catheter-based administration
of its Generx™ product candidate. The new system, which
includes automated syringe pumps, provides accurate and reproducible
delivery
at a standardized infusion rate for the volumes specified in the
AWARE study protocol. Additional features include an intuitive
workflow driven user interface, active and passive safety features
and an infusion data logging feature.
"Our new automated system provides a simpler and more uniform
method of administration for clinical investigators and is one
of several improvements we have introduced in order to optimize
our Phase 3 AWARE study, which we now expect to begin shortly," stated
Christopher J. Reinhard, Chairman and Chief Executive Officer of
Cardium Therapeutics.
About Cardium
Cardium Therapeutics, Inc. and its
subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company,
are medical technology companies
primarily focused on the development, manufacture and sale of innovative
therapeutic products and devices for cardiovascular, ischemic and
related indications. In October 2005, Cardium acquired a portfolio
of growth factor therapeutics from the Schering AG Group, Germany,
including the later-stage product candidate, Generx™, a DNA-based
growth factor therapeutic which is advancing to a Phase 3 clinical
study and is being developed for potential use by interventional
cardiologists as a one-time treatment to promote and stimulate
the growth of collateral circulation in the hearts of patients
with ischemic conditions such as recurrent angina. For more information
about Cardium and its businesses, products and therapeutic candidates,
please visit www.cardiumthx.com or
view its brochure.
In March 2006, Cardium acquired the technologies and products
of InnerCool Therapies, Inc., a San Diego-based medical technology
company in the emerging field of temperature modulation therapy
to rapidly and controllably cool the body in order to reduce cell
death and damage following acute ischemic events such as cardiac
arrest or stroke, and to potentially lessen or prevent associated
injuries such as adverse neurological outcomes. For more information
about Cardium's InnerCool subsidiary and therapeutic hypothermia,
including its Celsius Control System™, which has now received
regulatory clearance in the U.S., Europe and Australia, please
visit www.innercool.com.
In August 2006, Cardium acquired the technologies and products
of the Tissue Repair Company (TRC), a San Diego-based biopharmaceutical
company focused on the development of growth factor therapeutics
for the treatment of severe chronic diabetic wounds. TRC's lead
product candidate, Excellarate, is a DNA-activated collagen gel
for topical treatment formulated with an adenovector delivery carrier
encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate
is initially being developed to be administered once or twice for
the potential treatment of non-healing diabetic foot ulcers. Other
potential applications for TRC's Gene Activated Matrix™ (GAM)
technology include therapeutic angiogenesis (cardiovascular ischemia,
peripheral arterial disease) and orthopedic products, including
hard tissue (bone) and soft tissue (ligament, tendon, cartilage).
For more information about Cardium's Tissue Repair Company subsidiary,
please visit www.t-r-co.com.
Forward-Looking Statements
Except for statements
of historical fact, the matters discussed in this press release
are forward looking and reflect numerous
assumptions and involve a variety of risks and uncertainties, many
of which are beyond our control and may cause actual results to
differ materially from stated expectations. For example, there
can be no assurance that results or trends observed in one clinical
study will be reproduced in subsequent studies, that our clinical
trials can be initiated and conducted in a timely and effective
manner, that clinical trials and other efforts to accelerate the
development of our Generx™ product candidate will be successful,
that necessary regulatory approvals will be obtained, that our
actual or proposed products and treatments will prove to be sufficiently
safe and effective, that competing products will not be safer,
more effective or less expensive, that third parties on whom we
depend will perform as anticipated, or that our products or product
candidates will lead to value enhancing or partnering opportunities.
Actual results may also differ substantially from those described
in or contemplated by this press release due to risks and uncertainties
that exist in our operations and business environment, including,
without limitation, our limited experience in the development,
testing and marketing of therapeutic product candidates, risks
and uncertainties that are inherent in the conduct of human clinical
trials, including the timing and costs of such trials, our dependence
upon proprietary technology, our history of operating losses and
accumulated deficits, our reliance on collaborative relationships
and critical personnel, and current and future competition, as
well as other risks described from time to time in filings we make
with the Securities and Exchange Commission. We undertake no obligation
to release publicly the results of any revisions to these forward-looking
statements to reflect events or circumstances arising after the
date hereof.
Copyright 2007 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use Privacy Policy, please visit www.cardiumthx.com.
Cardium
Therapeutics™ and Generx™ are trademarks of Cardium
Therapeutics, Inc.
Gene Activated Matrix™ and GAM™ are trademarks
of Tissue Repair Company.
InnerCool Therapies®, InnerCool® and
Celsius Control System™
are trademarks of InnerCool Therapies, Inc.
SOURCE: Cardium Therapeutics, Inc. |
